BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26327629)

  • 1. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
    Pasquini MC; Zhang MJ; Medeiros BC; Armand P; Hu ZH; Nishihori T; Aljurf MD; Akpek G; Cahn JY; Cairo MS; Cerny J; Copelan EA; Deol A; Freytes CO; Gale RP; Ganguly S; George B; Gupta V; Hale GA; Kamble RT; Klumpp TR; Lazarus HM; Luger SM; Liesveld JL; Litzow MR; Marks DI; Martino R; Norkin M; Olsson RF; Oran B; Pawarode A; Pulsipher MA; Ramanathan M; Reshef R; Saad AA; Saber W; Savani BN; Schouten HC; Ringdén O; Tallman MS; Uy GL; Wood WA; Wirk B; Pérez WS; Batiwalla M; Weisdorf DJ
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):248-257. PubMed ID: 26327629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
    Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
    Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
    Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
    Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.
    Fang M; Storer B; Estey E; Othus M; Zhang L; Sandmaier BM; Appelbaum FR
    Blood; 2011 Aug; 118(6):1490-4. PubMed ID: 21680797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.
    Kayser S; Zucknick M; Döhner K; Krauter J; Köhne CH; Horst HA; Held G; von Lilienfeld-Toal M; Wilhelm S; Rummel M; Germing U; Götze K; Nachbaur D; Schlegelberger B; Göhring G; Späth D; Morlok C; Teleanu V; Ganser A; Döhner H; Schlenk RF;
    Blood; 2012 Jan; 119(2):551-8. PubMed ID: 22096250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype.
    Wudhikarn K; Van Rheeden R; Leopold C; Rattanaumpawan P; Gingrich R; de Magalhaes Silverman M
    Eur J Haematol; 2012 Oct; 89(4):294-301. PubMed ID: 22762733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
    Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
    Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
    Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
    Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Harada K; Konuma T; Machida S; Mori J; Aoki J; Uchida N; Ohashi K; Fukuda T; Tanaka M; Ikegame K; Ozawa Y; Iwato K; Eto T; Onizuka M; Ichinohe T; Atsuta Y; Yano S
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1730-1743. PubMed ID: 31054982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.